Erik H van Beers
Overview
Explore the profile of Erik H van Beers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calandrini C, Verhagen O, Tissoudali A, Homburg C, Vessies J, Brussee M, et al.
Vox Sang
. 2024 Dec;
120(2):170-177.
PMID: 39647598
Background And Objectives: To test the performance of a new droplet digital polymerase chain reaction (ddPCR) non-invasive foetal blood group and platelet antigen genotyping assay in the setting of a...
2.
Chen Y, Valent E, van Beers E, Kuiper R, Oliva S, Haferlach T, et al.
Int J Lab Hematol
. 2021 Aug;
44(1):127-134.
PMID: 34448362
Objectives: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible, possibly limiting the generalizability of...
3.
Kuiper R, Zweegman S, van Duin M, van Vliet M, van Beers E, Dumee B, et al.
Blood Adv
. 2020 Dec;
4(24):6298-6309.
PMID: 33351127
The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older...
4.
van Beers E, Huigh D, Bosman L, de Best L, Kuiper R, Spaan M, et al.
J Mol Diagn
. 2020 Nov;
23(1):120-129.
PMID: 33152501
Multiple myeloma (MM) is an incurable plasma cell cancer with a large variability in survival. Patients with MM classified as high risk by the SKY92 gene expression classifier are at...
5.
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Ubels J, Sonneveld P, van Beers E, Broijl A, van Vliet M, de Ridder J
Nat Commun
. 2018 Jul;
9(1):2943.
PMID: 30054467
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can...
6.
Gaultney J, Ng T, Uyl-de Groot C, Sonneveld P, van Beers E, van Vliet M, et al.
Pharmacogenomics
. 2018 Jan;
19(3):213-226.
PMID: 29334316
Biomarkers associated with prognosis in multiple myeloma (MM) can be used to stratify patients into risk categories. An attractive alternative to uniform treatment (UT), risk-stratified treatment (RST) is proposed where...
7.
van Beers E, van Vliet M, Kuiper R, de Best L, Anderson K, Chari A, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Jul;
17(9):555-562.
PMID: 28735890
Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify...
8.
Kuiper R, van Duin M, van Vliet M, Broijl A, van der Holt B, El Jarari L, et al.
Blood
. 2015 Sep;
126(17):1996-2004.
PMID: 26330243
Patients with multiple myeloma have variable survival and require reliable prognostic and predictive scoring systems. Currently, clinical and biological risk markers are used independently. Here, International Staging System (ISS), fluorescence...
9.
van Vliet M, Dumee B, Simons E, Bullinger L, Dohner K, Dohner H, et al.
Genet Test Mol Biomarkers
. 2013 Mar;
17(4):295-300.
PMID: 23530539
Mutations in the gene encoding nucleophosmin (NPM1) carry a prognostic value for patients with acute myeloid leukemia (AML). Various techniques are currently being used to detect these mutations in routine...
10.
Brand J, van Vliet M, de Best L, Valk P, Vietor H, Lowenberg B, et al.
Exp Hematol Oncol
. 2013 Mar;
2(1):7.
PMID: 23497432
High levels of BAALC, ERG, EVI1 and MN1 expression have been associated with shorter overall survival in AML but standardized and clinically validated assays are lacking. We have therefore developed...